Get in Touch


NIBEC TOPscovery: anti-fibrosis peptide therapeutic programs and target tissue penetrating peptide

San Francisco/January 14, 2020 – NIBEC Co., Ltd., today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square.

Dr. Yoon Jeong Park, CTO will be presenting NIBEC Co., Ltd. at Biotech Showcase as follows:

Date: January 14, 2020

Time: PM 2:30 (PST)

Room: Yosemite C (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

Information about NIBEC presentation

NIBEC has peptide therapeutic programs which was developed by NIBEC’s own peptide discovery technology. Peptide therapeutic programs are focused on resolve fibrosis in liver, lung and heart. In addition, the platform technology of target tissue penetrating peptide carrier (NIPEP-TPP) can be applied to protein, antibody which have intracellular target. This NIPEP-TPP increase efficiency and decrease side effect to non-target, which is currently applied in oncology.

Quote from Dr. Chong Pyung Chung, CEO of NIBEC

We would like to have meeting with global big pharmas and other biotechs who are interested in our technology. We are expecting to introduce our peptide programs for anti-fibrosis in NASH and pulmonary disease and target tissue penetrating peptide technology in company presentation and we will discuss therapeutic programs in partnering meeting. We are open to any types of collaboration. 



NIBEC is established as a spin-off venture from Seoul National University technology at 2004 and listed in KOSDAQ at 2011. The company's main technology is based on peptide platform for drug discovery and development. In addition, NIBEC has target tissue penetrating peptide delivery platform to deliver protein/antibody into the target tissue. The therapeutic area the company focuses are fibrotic inflammatory diseases (NASH, Pulmonary & Cardiac fibrosis and IBD) and cancer. In addition to the drug development, the company holds medical device manufacturer license for tissue engineering, regenerative therapy. The company has two research institutes and one manufacturing facility with fully granted GMP.


Dr. Jue-Yeon Lee, Director of Research Institute

TEL:+82-80-765-1976, FAX: +82-2-747-9647,

Key Takeaways
  • Peptide therapeutics
  • Anti-fibrosis, NASH, IBD
  • target tissue penetrating peptide delivery
Media Gallery
Dr. JUE YEON LEE, Director of Research Institute